LAG-3 and PD-1+LAG-3 inhibition promote anti-tumor immune responses in human autologous melanoma/T cell co-cultures

por Gestermann, Nicolas, Saugy, Damien, Martignier, Christophe, Tillé, Laure, Fuertes Marraco, Silvia A., Zettl, Markus, Tirapu, Iñigo, Speiser, Daniel E., Verdeil, Grégory
Publicado 2020

Distinct immune stimulatory effects of anti-human VISTA antibodies are determined by Fc-receptor interaction

por Mostböck, Sven, Wu, Helen Haixia, Fenn, Timothy, Riegler, Bettina, Strahlhofer, Susanne, Huang, Yining, Hansen, Gale, Kroe-Barrett, Rachel, Tirapu, Iñigo, Vogt, Anne B.
Publicado 2022

LY6G6D is a selectively expressed colorectal cancer antigen that can be used for targeting a therapeutic T-cell response by a T-cell engager

por Corrales, Leticia, Hipp, Susanne, Martin, Katharina, Sabarth, Nicolas, Tirapu, Iñigo, Fuchs, Klaus, Thaler, Barbara, Walterskirchen, Christian, Bauer, Kathrin, Fabits, Markus, Bergmann, Michael, Binder, Carina, Chetta, Paolo ML., Vogt, Anne B., Adam, Paul J.
Publicado 2022

Combination of two novel blocking antibodies, anti-PD-1 antibody ezabenlimab (BI 754091) and anti-LAG-3 antibody BI 754111, leads to increased immune cell responses

por Zettl, Markus, Wurm, Melanie, Schaaf, Otmar, Mostböck, Sven, Tirapu, Iñigo, Apfler, Ilse, Lorenz, Ivo C., Frego, Lee, Kenny, Cynthia, Thibodeau, Michael, Oquendo Cifuentes, Elisa, Reschke, Markus, Moll, Jürgen, Kraut, Norbert, Vogt, Anne, Sedgwick, Jonathon D., Waizenegger, Irene C.
Publicado 2022